Загрузка...
Post Hoc Health‐Related Quality of Life Analysis According to Response Among Patients with Prostate Cancer in the PROSELICA and FIRSTANA Studies
BACKGROUND: The phase III PROSELICA (NCT01308580) and FIRSTANA (NCT01308567) trials investigated taxane chemotherapy among men with postdocetaxel metastatic, castration‐resistant prostate cancer (mCRPC) or chemotherapy‐naïve mCRPC, respectively. We present a post hoc analysis of patient‐reported hea...
Сохранить в:
| Опубликовано в: : | Oncologist |
|---|---|
| Главные авторы: | , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley & Sons, Inc.
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8265338/ https://ncbi.nlm.nih.gov/pubmed/33904646 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13803 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|